RIDDLE&CODE
16.12.2021 13:07:56 CET | Business Wire | Press release
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, together with the largest energy provider in Austria, Wien Energie, have announced the successful launch of a blockchain-powered energy tokenization platform called MyPower. The platform puts everyday consumers in charge of a co-created energy future by offering micro-investments and the tokenization of produced kilowatt-hours (kWh).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005004/en/
“Local energy communities and microgrids are expected to play an increasingly important role in addressing climate change challenges and the transition towards renewable and sustainable energy systems,” said Michael Strebl, CEO of Wien Energie. “However, the current market structure is inadequate to realise this vision, as consumers are practically excluded from participating in energy production and settlements. Blockchain has the potential to transform consumers into prosumers and active participants in the energy network.”
With the MyPower platform, which combines RIDDLE&CODE’s deep next-gen technology expertise with Wien Energie’s industry know-how, the two companies have managed to bridge this gap. As part of the project, RIDDLE&CODE Energy Solutions provides key management, tokenization and custody services and utilises Intel® Software Guard Extensions (Intel® SGX) to deliver the highest level of security.
The blockchain-powered platform enables consumers to participate in both energy consumption and production and benefit from using green energy. MyPower tokenizes solar photovoltaic (PV) assets and allows consumers to purchase shares in PV plants across Austria. At the MVP stage of the project, shares of a small, local PV plant were sold to a limited number of consumers. In return for their participation, consumers received a certain number of tokens, based on the amount of energy produced by the PV plant. The accumulated tokens could then be used for various purposes, such as paying electric bills.
“Confidential computing with Intel® Software Guard Extensions enables companies to leverage the benefits of confidential computing and allows data owners to remain in control of their sensitive data,” says Paul O’Neill, Senior Director, Business Development in Intel’s Confidential Computing Group. “RIDDLE&CODE's launch with Wien Energy demonstrates how Intel® SGX can help to deliver the security foundation needed to build and deploy a new era of dynamic and cost-effective networks. Intel® SGX offers hardware-based memory encryption that isolates specific application code and data in memory. Intel® SGX allows RIDDLE&CODE to allocate private regions of memory, called enclaves, which are designed to be protected from processes running at higher privilege levels.”
“Through the tokenization of both digital and physical assets, RIDDLE&CODE enables new business models in the financial, mobility and, of course, energy industries,” said Thomas Fürstner, Founder and CTO of RIDDLE&CODE. “Together with Wien Energie, we will unlock the full potential of the energy marketplaces and provide consumers with a platform that is both flexible and trustworthy.”
Please download related images to use in your articles from www.riddleandcode.com//press-mypower .
RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, provides the blockchain-powered infrastructure that enables resilient, low-cost and green electricity production and builds a foundation for a decentralised urban energy marketplace.
More information: www.riddleandcode.com
Wien Energie
Wien Energie is one of Austria’s largest utility providers, responsible for ensuring the reliable and eco-friendly supply of electricity, natural gas and heating to around two million people, 230,000 businesses and industrial facilities, and 4,500 farms in the Greater Vienna metropolitan area. Wien Energie is also involved in a number of projects at European level.
More information: www.wienenergie.at .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom